Matthew Kaplan
Stock Analyst at Ladenburg Thalmann
(2.75)
# 1,635
Out of 5,182 analysts
25
Total ratings
60.87%
Success rate
17.81%
Average return
Main Sectors:
Stocks Rated by Matthew Kaplan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $319 → $344 | $566.99 | -39.33% | 9 | Oct 31, 2024 | |
| URGN UroGen Pharma | Maintains: Buy | $48 → $54 | $23.77 | +125.07% | 1 | Jun 14, 2024 | |
| TGTX TG Therapeutics | Maintains: Buy | $39 → $40 | $35.38 | +13.06% | 3 | May 2, 2024 | |
| LQDA Liquidia | Maintains: Buy | $15 → $30 | $37.34 | -19.66% | 2 | Dec 21, 2023 | |
| ARDX Ardelyx | Maintains: Buy | $7.5 → $8.5 | $5.99 | +41.90% | 4 | Aug 3, 2023 | |
| KPRX Kiora Pharmaceuticals | Reiterates: Buy | $1,071 | $2.32 | +46,063.79% | 2 | Feb 8, 2023 | |
| XAIR Beyond Air | Maintains: Buy | $340 → $460 | $0.49 | +94,336.46% | 1 | Jun 29, 2022 | |
| LPCN Lipocine | Upgrades: Buy | $51 | $2.37 | +2,051.90% | 1 | Dec 10, 2020 | |
| COGT Cogent Biosciences | Initiates: Buy | $16 | $36.61 | -56.29% | 1 | Oct 14, 2020 | |
| TARA Protara Therapeutics | Initiates: Buy | $45 | $4.99 | +801.80% | 1 | Jan 22, 2020 |
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $319 → $344
Current: $566.99
Upside: -39.33%
UroGen Pharma
Jun 14, 2024
Maintains: Buy
Price Target: $48 → $54
Current: $23.77
Upside: +125.07%
TG Therapeutics
May 2, 2024
Maintains: Buy
Price Target: $39 → $40
Current: $35.38
Upside: +13.06%
Liquidia
Dec 21, 2023
Maintains: Buy
Price Target: $15 → $30
Current: $37.34
Upside: -19.66%
Ardelyx
Aug 3, 2023
Maintains: Buy
Price Target: $7.5 → $8.5
Current: $5.99
Upside: +41.90%
Kiora Pharmaceuticals
Feb 8, 2023
Reiterates: Buy
Price Target: $1,071
Current: $2.32
Upside: +46,063.79%
Beyond Air
Jun 29, 2022
Maintains: Buy
Price Target: $340 → $460
Current: $0.49
Upside: +94,336.46%
Lipocine
Dec 10, 2020
Upgrades: Buy
Price Target: $51
Current: $2.37
Upside: +2,051.90%
Cogent Biosciences
Oct 14, 2020
Initiates: Buy
Price Target: $16
Current: $36.61
Upside: -56.29%
Protara Therapeutics
Jan 22, 2020
Initiates: Buy
Price Target: $45
Current: $4.99
Upside: +801.80%